Tuesday August 11, 2026 7:30 AM ET

Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Tuesday August 4, 2026 8:00 AM ET

Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026

Wednesday July 15, 2026 7:45 AM ET

Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)

Wednesday July 1, 2026 8:00 AM ET

Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6

Thursday May 14, 2026 8:00 AM ET

Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award

Thursday May 7, 2026 4:06 PM ET

Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Wednesday April 15, 2026 9:15 AM ET

Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation

Friday March 27, 2026 4:12 PM ET

Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update

Tuesday March 24, 2026 8:00 AM ET

Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US

Thursday March 12, 2026 7:30 AM ET

Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study

Friday March 6, 2026 7:47 AM ET

Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement